Palmar fasciitis and arthritis associated with cancer of the prostate
Van den Bergh, L.; Vanneste, S.B.; Knockaert, D.C.
Acta Clinica Belgica 46(2): 106-110
1991
ISSN/ISBN: 1784-3286 PMID: 1649528 Document Number: 378783
A case of palmar fasciitis and arthritis (PFA) is described in a man with both a prolactinoma and metastatic cancer of the prostate. This rare condition is mainly described in women with ovarian cancer and our case is the first reported association of PFA with cancer of the prostate.
Document emailed within 1 workday
Related Documents
Grados, F.; Houvenagel, E.; Cayrolle, G.; Bellony, R.; Fardellone, P.; Sebert, J.L. 1998: Two new cancer locations accompanied with palmar fasciitis and polyarthritis Revue du Rhumatisme 65(3): 212-214Valverde-Garcia, J.; Juanola-Roura, X.; Ruiz-Martin, J.M.; Nolla-Sole, J.M.; Rodriguez-Moreno, J.; Roig-Escofet, D. 1987: Paraneoplastic palmar fasciitis-polyarthritis syndrome associated with breast cancer Journal of Rheumatology 14(6): 1207-1209
Caron, P.; Lassoued, S.; Thibaut, I.; Fournie, B.; Fournie, A. 1989: Thyroid plasmacytoma with dermatomyositis and palmar fasciitis Journal of Rheumatology 16(7): 997-999
Giannakopoulos, C.K.; Kyriakidou, G.K.; Toufexi, G.E. 2005: Palmar fasciitis and polyarthritis associated with secondary ovarian carcinoma. Case report European Journal of Gynaecological Oncology 26(3): 339-341
Romppanen, J.; Haapalainen, T.; Punnonen, K.; Penttilä, I. 2002: Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer Anticancer Research 22(1a): 415-420
Murray, N.P.; Aedo, S.óc.; Reyes, E.; Fuentealba, C.; Jacob, O. 2019: Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy Archivos Espanoles de Urologia 72(1): 16-24
Brent, L.H.; Abruzzo, J.L. 1985: Localized eosinophilic fasciitis in a patient with rheumatoid arthritis Journal of Rheumatology 12(5): 987-989
Sun, S.-C.; Zhao, H.; Liu, R.; Wang, B.-L.; Liu, Y.-Q.; Zhao, Y.; Shi, Z.-D. 2017: Expression of long non-coding RNA H19 in prostate cancer and its effect on the proliferation and glycometabolism of human prostate cancer cells Zhonghua Nan Ke Xue 23(2): 120-124
Grosclaude, P.; Menegoz, F.; Schaffer, P.; Macé Lesec'h, J.; Arveux, P.; Le Mab, G.; Soulié, M.; Villers, A. 1997: Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990 Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(4): 647-654
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747
Liu, J-he.; Li, H-wei.; Tong, M.; Li, M.; Na, Y-qun. 2004: Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer Zhonghua Yi Xue Za Zhi 84(5): 364-368
Fourcade, R-Olivier.; Richaud, P.; Coloby, P.; Malavaud, B. 2007: Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 17(4 Suppl. 1): 891-910
Perrin, P.; François, O.; Maquet, J.H.; Bringeon, G.; Duteil, P.; Devonec, M. 1991: Circulating prostate cancer specific antigens in benign hypertrophy and localized cancer of the prostate Presse Medicale 20(28): 1313-1319
Liu, B.-q.; Wu, Y.-d.; Wei, J.-x.; Zhang, T.; Liu, R.-l.; Ma, T.-x. 2007: Expression of prostate cancer antigen-1 in prostate cancer and its clinical significance Zhonghua Nan Ke Xue 13(11): 997-1001
Zhu, X-Dong.; Zheng, A.; Wang, Z-Qian.; Shao, Q. 2018: Prostate Cancer Prevention Trial risk calculator for evaluating the risk of prostate cancer in the high-risk Chinese population Zhonghua Nan Ke Xue 24(2): 142-146
Wang, W.; Mo, Z.-N. 2010: Advances in prostate-specific membrane antigen targeted therapies for prostate cancer Zhonghua Nan Ke Xue 16(6): 547-551
Bostwick, D.G. 1994: Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer American Journal of Clinical Pathology 102(4 Suppl 1): S31-S37
Fornara, P.; Sturm, W.; Fabricius, P.G.; Schmiedt, E. 1987: Clinical relevance of radioimmunologic determination of prostate specific antigen in prostate cancer Der Urologe. Ausg. a 26(3): 158-161
Schäfer, U.; Micke, O.; Hampel, G.; Brandt, B.; Bovenschulte, A.; Semjonow, A.; Willich, N. 1997: The use of prostate-specific antigen (PSA) for the monitoring of radiation therapy in prostate cancer Anticancer Research 17(4b): 2983-2986